News|Articles|November 16, 2026

Positive Phase 3 Results: HLP003 as Adjunctive Treatment for Major Depressive Disorder

Author(s)Leah Kuntz
Listen
0:00 / 0:00

Key Takeaways

  • APPROACH used a multicenter, randomized, double-blind, placebo-controlled adjunctive design in DSM-5 MDD with baseline MADRS ≥24 and mean baseline scores ~33, maintaining background antidepressants throughout.
  • Efficacy at 6 weeks showed clinically meaningful separation: LS mean MADRS change -19.5 vs -11.9 for placebo (LSMD -7.6; P<0.0001; effect size 0.653).
SHOW MORE

HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as day 2.

Helus Pharma today announced positive topline results from the phase 3 pivotal APPROACH study evaluating deuterated psilocin (HLP003) as an adjunctive treatment for adults with major depressive disorder (MDD). HLP003 achieved statistically significant and clinically meaningful results in the primary, key secondary, and other secondary endpoints starting as early as day 2 and these were maintained at all time points.1

“The large unmet need for patients with major depressive disorder who continue to experience persistent symptoms underscores the importance of new rapid-acting and well-tolerated adjunctive treatment options,” said Michael Halstead, the chief executive pfficer of Helus Pharma. “We believe these data demonstrate a therapeutic profile that has the potential to meaningfully improve outcomes for patients and strengthen our momentum as we continue to progress HLP003 toward regulatory approval and potential commercialization.”

About APPROACH Study and the Phase 3 Program

APPROACH is a phase 3, multicenter, randomized, parallel-group, double blind, placebo-controlled study of HLP003 as an adjunctive treatment for adult participants with MDD. The phase 3 study evaluated the efficacy and safety of HLP003 compared with placebo. The intent-to-treat population consisted of 222 participants with a DSM-5 confirmed diagnosis of moderate to severe MDD as indicated by a MADRS total score of at least 24 at screening and baseline.

The baseline MADRS total scores were 32.7 for HLP003 and 33.8 for the placebo. Participants continued taking their stable dose of antidepressant medication throughout the study.

APPROACH is the first of the 3 studies in the PARADIGM phase 3 program. The program also includes EMBRACE, a second pivotal study which is currently ongoing, and the EXTEND study. EXTEND is the ongoing long-term extension study which will provide additional data on long-term safety, durability of effect, and the potential role of redosing. Participants from APPROACH and EMBRACE may roll into EXTEND. Helus expects to report topline results from the EMBRACE trial in quarter 4 of 2027.

Results

At the primary endpoint of 6 weeks, the least squares (LS) mean reduction from baseline in the MADRS total score for HLP003 was 19.5 points vs 11.9 points for placebo (LS mean difference = -7.6 points, P<0.0001, effect size=0.653).

The rapid onset of action with HLP003 was demonstrated with statistically significant LS mean MADRS reductions as early as day 2 of 16.1 points vs 11.0 points for placebo (LS mean difference = -5.0 points, P=0.0013, effect size=0.438). This effect was durable with an LS mean reduction from baseline in the MADRS total score for HLP003 of 16.9 points vs 9.9 points for placebo (LS mean difference = -7.0 points, P<0.0001, effect size=0.581) at the key secondary endpoint of 12 weeks.

Additionally, HLP003 demonstrated statistically significant improvements on the Clinical Global Impression Scale compared with placebo starting as early as day 2 and maintained at all time points.

“The results from the APPROACH study set a new benchmark for what may be achievable with adjunctive treatment in major depressive disorder,” said Roger S. McIntyre, MD, FRCPC, a professor of psychiatry and pharmacology at the University of Toronto. “The magnitude of benefit observed in this study is highly compelling and has the potential to redefine expectations among clinicians treating patients who continue to experience depressive symptoms while on an anti-depressant.”

Unmet Need

According to research, approximately two-thirds of patients with MDD do not achieve remission with first-line antidepressant treatment.2

By adding a therapy to an existing antidepressant regimen, psychiatric clinicians may be able to enhance patient treatment response while avoiding the need for antidepressant discontinuation, medication washout periods, or the potential withdrawal symptoms associated with switching treatments.

Safety Profile

HLP003 was generally well tolerated in the APPROACH study. Most adverse events were mild to moderate in severity, transient, and primarily limited to the day of dosing. There were 3 HLP003 treatment-related serious adverse events in the study. No new safety signals were identified.

References

1. Helus Pharma announces positive topline results from phase 3 APPROACH study evaluating HLP003 as adjunctive treatment in major depressive disorder. News release. November 16, 2026. Accessed November 16, 2026. https://ir.helus.com/news-releases/news-release-details/helus-pharma-announces-positive-topline-results-phase-3-approach

2. Pigott HE, Kim T, Xu C, et al. What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study's patient-level data with fidelity to the original research protocol. BMJ Open. 2023;13(7):e063095.


Related to this article